Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vistagen Therapeutics Inc
(NQ:
VTGN
)
4.710
+0.010 (+0.21%)
Streaming Delayed Price
Updated: 1:15 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
47,776
Open
4.680
Bid (Size)
4.700 (1)
Ask (Size)
4.710 (1)
Prev. Close
4.700
Today's Range
4.655 - 4.760
52wk Range
1.620 - 24.71
Shares Outstanding
9,362,444
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
7 Stocks Under $15 Predicted to Boom in the Next 2 Years
Today 7:13 EDT
Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy.
Via
InvestorPlace
Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027
April 09, 2024
Explore three stocks under $10 in electronic equipment and instruments, technology hardware, storage and peripherals, and biotechnology.
Via
InvestorPlace
Performance
YTD
-8.54%
-8.54%
1 Month
+13.49%
+13.49%
3 Month
-1.87%
-1.87%
6 Month
+56.48%
+56.48%
1 Year
+10.56%
+10.56%
More News
Read More
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation at Upcoming Anxiety and Depression Association Conference
April 09, 2024
Via
Investor Brand Network
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
April 09, 2024
From
Vistagen
Via
Business Wire
Recap: Vistagen Therapeutics Q3 Earnings
February 13, 2024
Via
Benzinga
VistaGen Therapeutics's Earnings: A Preview
February 12, 2024
Via
Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Appointment of New VP of Translational Medicine
April 01, 2024
Via
Investor Brand Network
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
April 01, 2024
From
Vistagen
Via
Business Wire
Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027
March 31, 2024
Via
InvestorPlace
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Announces Participation at Upcoming Stifel 2024 Virtual CNS Days
March 11, 2024
Via
Investor Brand Network
Vistagen to Present at Stifel 2024 Virtual CNS Days
March 11, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present at TD Cowen Conference
February 28, 2024
Via
Investor Brand Network
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Vistagen
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
February 19, 2024
Via
Benzinga
3 Revolutionary Biotech Stocks Poised for 10X Surge
February 19, 2024
Via
InvestorPlace
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
February 14, 2024
Via
InvestorPlace
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Releases Q3 2024 Financial Report, Corporate Update
February 14, 2024
Via
Investor Brand Network
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
February 13, 2024
From
Vistagen
Via
Business Wire
Earnings Scheduled For February 13, 2024
February 13, 2024
Via
Benzinga
3 Penny Stocks to Buy for the Next Bull Run: February 2024
February 07, 2024
Via
InvestorPlace
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q3 Results, Conference Call
February 06, 2024
Via
Investor Brand Network
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
February 06, 2024
From
Vistagen
Via
Business Wire
3 Penny Stocks to Turn $999 Into $1 Million: January 2024
January 26, 2024
Via
InvestorPlace
Topics
Economy
Exposures
Economy
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) AV-101 to Receive Patent from EPO to Treat Neuropathic Pain
December 27, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
December 27, 2023
From
Vistagen
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.